Developer docs
API playgroundTry for free, no card

Search company profiles

Amferia

Full company profile

uuid0002qsi

Namestring
Amferia
Legal namestring
Amferia AB
Websiteurl
amferia.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Amferia is a Swedish medtech company founded in 2018 that develops and commercializes antimicrobial hydrogel wound dressings based on a proprietary amphiphilic antimicrobial peptide (AMP) hydrogel platform. The core technology permanently conjugates antimicrobial peptides to a hydrogel matrix, protecting them from enzymatic degradation while allowing the peptides to physically puncture bacterial cell membranes, killing 99.99% of bacteria including antibiotic-resistant strains such as MRSA, MDR E. coli, and Pseudomonas aeruginosa. The platform is protected by three patent families granted in Europe, the United States, and China, and the human-care wound dressing received FDA De Novo Classification in February 2026, establishing a new regulatory category for antibacterial peptide-based wound dressings.

The company's commercial operations are concentrated in veterinary/animal health wound care, where its products are sold through a network of distribution partners across eight European countries under the Snögg BactiDefend brand (via Orkla Wound Care for Nordic, Germany, Spain, and Portugal), Biokema (Switzerland), Grovet (Benelux), Magnum Veterinaaria (Baltic States), and Triolab (Sweden). The company generates revenue through B2B hardware sales to veterinary clinics and is now commercializing human-care wound dressings in the United States following FDA approval, with CE marking pending for European human-health launch. Pipeline products include pre-surgery antibacterial patches, antimicrobial sprays developed in collaboration with Medspray, and antibacterial coatings for medical devices such as catheters and implants, alongside potential licensing opportunities for the underlying platform technology.

Amferia operates from a small team of approximately seven people based at the AZ BioVentureHub in Mölndal, Sweden, with a US sales office (Amferia US LLC) in Bonita, California. The company has raised approximately €7M+ in cumulative venture funding from Chalmers Ventures, Almi Invest, and angel investors, including a €3.5M round in December 2025 led by existing shareholders and new investors prominent in global wound care. Strategic leadership includes co-founder Anand Rajasekharan as CEO, co-founder Saba Atefyekta as Sales & Marketing Director (recipient of King Carl XVI Gustaf's New Entrepreneur of the Year Award), and R&D Director Martin Andersson, with recent board additions of former Mölnlycke executive Randy Schwartz and ex-Pfizer/Orexo CEO Nikolaj Sørensen to guide US market entry and global expansion.

Short descriptiontext

Amferia is a Swedish medtech company that develops antimicrobial peptide-hydrogel wound dressings that physically kill antibiotic-resistant bacteria, serving veterinary clinics across eight European countries via distribution partners and entering the US human healthcare market following FDA De Novo approval in February 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMölndal, Sweden
HQ citystring
Mölndal
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial wound dressings, medical device coatings, veterinary wound care, peptide hydrogel technology, antibiotic resistance solutions
Industry1 code
PRIMARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Antimicrobial Wound Care Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Animal Health Products
TypeHardware Sales
Description

Sale of antimicrobial hydrogel wound dressings for veterinary applications through distribution partners. Products sold under brand names like Snögg BactiDefend through Orkla Wound Care. Revenue generated from product sales to veterinary clinics across Europe.

amferia.com
2Human Health Products
TypeHardware Sales
Description

Planned revenue from antibacterial wound dressings and other human healthcare applications pending regulatory approvals (FDA, CE marking). Products will be sold through partnerships with established wound care companies or direct commercialization.

amferia.com
3Licensing and Partnership Agreements
TypeLicensing Royalties
Description

Technology licensing opportunities for the antimicrobial peptide-hydrogel platform in various medical device applications including coatings, sprays, and implant sterilization.

amferia.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1B2B wholesale pricing through distribution partners
ModelOtherBilling cadenceMulti-year contract
Notes

Products are sold through authorized distribution partners (Orkla Wound Care, Biokema, Grovet, Magnum Veterinaaria, Triolab) under private label or co-branding arrangements. Pricing is negotiated through partnerships rather than publicly listed.

amferia.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Amferia develops and manufactures antimicrobial hydrogel medical products based on a proprietary amphiphilic platform that permanently binds antimicrobial peptides, enabling physical bacterial killing without releasing active substances. Core offerings include veterinary and human wound dressings (AMP Wound Dressing / Snögg BactiDefend), with pipeline products spanning pre-surgery patches, aerosol sprays for deep wounds, and antimicrobial coatings for medical devices such as catheters and implants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 99.99% bacterial kill rate including antibiotic-resistant strains (MRSA, MDR E. Coli, Pseudomonas aeruginosa)
+5 more records
Product overview1 text field

Amferia offers an antimicrobial peptide hydrogel platform technology that enables peptides to be used safely in medical devices. The core product is the AMP Wound Dressing for animal health (branded as Snögg BactiDefend Dressing in partnership with Orkla) and the human care Antimicrobial Hydrogel Wound Dressing (which received FDA De Novo Classification in February 2026 as the world's first antibacterial peptide-based wound dressing). Pipeline products include Antibacterial Patches for pre-surgery applications, Antimicrobial Sprays for wound care (developed with Medspray), and Antibacterial Coatings for medical devices such as catheters and implants. The platform technology consists of amphiphilic antimicrobial hydrogels with permanently bonded peptides that physically puncture bacterial membranes, killing 99.99% of bacteria including resistant strains without releasing substances into the body.

Product and service6 records
1AMP Wound Dressing (Animal Health)
CategoryAntimicrobial Wound Dressings
Description

Antimicrobial hydrogel wound dressing for veterinary use that kills up to 99.99% of bacteria upon contact, including antibiotic-resistant strains. The dressing consists of amphiphilic antibacterial polymers mimicking the immune system, bound in place so nothing is released into the wound. For professional veterinary in-clinic use in surgical care units or in-patient care.

2Snögg BactiDefend Dressing
CategoryAntimicrobial Wound Dressings
Description

Veterinary wound care product using Amferia's proprietary antimicrobial hydrogel technology, sold under Orkla's Snögg Animal Care brand via exclusive distribution agreement. Designed for professional veterinary use across multiple European countries (Nordic region, Germany, Spain, Portugal).

3Antimicrobial Hydrogel Wound Dressing (Human Care)
CategoryAntimicrobial Wound Dressings
Description

Antibacterial wound dressing featuring patented hydrogel permanently bonded with peptides that physically puncture bacterial cell membranes, killing 99.99% of bacteria including antibiotic-resistant strains without releasing active substances into the body or wound. For human patients in hospitals, wound care clinics, and healthcare institutions.

4Antibacterial Patches (Pre-Surgery)
CategoryAntimicrobial Skin Preparation
Description

Patch formulation of Amferia hydrogel that clears skin of bacteria before surgical procedures. Demonstrated to kill up to 99.99% of bacteria on skin surface within three hours of application in a clinical study with 40 healthy volunteers.

5Antimicrobial Spray
CategoryAntimicrobial Spray Formulations
Description

Aerosol spray formulation of the antimicrobial hydrogel for application directly to wounds or skin. Enables eradication of bacteria from deep and uneven wounds with high surface area coverage. Developed in partnership with Medspray BV via Eurostars Grant (SURPAS project).

6Antibacterial Coatings (Medical Devices)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-05
Description

Distribution partnership to expand AMP Wound Dressing into Benelux markets (Netherlands, Belgium, Luxembourg). Grovet is a major player in animal health market across Benelux. Products expected to be available by spring 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-20
Description

Distribution partnership to expand into Baltic States (Latvia, Lithuania, Estonia). Partnership aims to bring groundbreaking wound care technology to animal patients in the Baltics, helping reduce reliance on antibiotics in veterinary practice.

3Biokema SA
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-08-26
Description

Distribution partnership for commercialization of Amferia's wound care technology for animal health in Switzerland. Swiss company founded in 1959 specializing in veterinary pharmaceuticals and products. Products to be marketed starting early 2025.

amferia.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-26
Description

Eurostars grant-funded collaboration (SURPAS project) to develop antimicrobial spray for surgical wound care. Medspray provides microdroplet spray technology expertise while Amferia contributes peptide-hydrogel material. Joint project aims to deliver peptide-hydrogel as microdroplet spray with optimal coverage for wound care applications.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-04
Description

Exclusive animal health private label license and purchase agreement covering Nordic region, Germany, Spain, and Portugal for 3 years with possibility for extension. Products marketed under Orkla's Snögg Animal Care brand. This is Amferia's largest distribution partnership, with Orkla being a publicly listed company on the Norwegian Stock Exchange.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-05-06
Description

Distribution partnership to reach Swedish veterinary market. Products marketed to selective veterinary clinics across Sweden with further expansion planned for 2022.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration partner where Amferia's technology was originally developed. Ongoing collaboration on new product development, pre-clinical studies, and clinical research. Co-developed mesoporous elastomer technology and spray formulations.

8AZ BioVentureHub
Strategic tierMinorTypeOthers
Description

Life science innovation hub located in Mölndal, Sweden (formerly AstraZeneca's facility) where Amferia established R&D operations in October 2019. Provides supportive environment with state-of-the-art infrastructure for medtech and life science companies.

amferia.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global advanced wound care and ostomy player (Aquacel, Foam dressings). Competes in the same antimicrobial/advanced dressing category and is a logical partner for Amferia's peptide-hydrogel licensing.

TypeDirect peer
Description

Major medical device company with significant advanced wound care franchise (Allevyn, PICO). Overlapping customer base (hospitals, wound clinics) and a likely competitor or partner once peptide-based dressings reach commercial scale.

TypeDirect peer
Description

Swedish medtech specializing in antimicrobial coatings for medical devices (catheters, implants) — directly comparable technology adjacency. Amferia board chair Agneta Edberg was previously COO of Bactiguard, underscoring the strategic proximity.

TypeDirect peer
Description

One of the world's largest advanced wound care companies (Mepilex, Mepitel, etc.). Direct competitor in advanced wound dressings and Amferia's most likely strategic acquirer or licensing partner; several Amferia board members (Randy Schwartz, Therese Rydell) joined from Mölnlycke.

TypeDirect peer
Description

US advanced wound care company (Apligraf, Dermagraft, PuraPly). Competes in the same wound care category with biologics and skin substitutes; comparable reimbursement-driven US go-to-market motion.

TypeEmerging player
Description

US-based advanced wound care and surgical recovery company (EpiFix, AmnioFix). Smaller, growth-stage competitor serving similar hospital and outpatient wound care customers.

TypeEmerging player
Description

Canadian antimicrobial coating and wound dressing company (e.g., IVClear, ColActive). Smaller and earlier-stage than the majors but addresses the same antimicrobial catheter/coating overlap as Amferia's coating pipeline.

TypeBroad incumbent
Description

Diversified surgical and wound care company (Integra dermal regeneration, wound matrices). Overlaps with Amferia in hospital wound care channels though through different technology.

TypeBroad incumbent
Description

Diversified healthcare giant with established advanced wound care dressings (Tegaderm). Comparable end market and channel access but competing as part of a much broader medical portfolio.

TypeDirect peer
Description

Danish medtech with a sizeable wound and skin care business (Biatain, Comfeel). Comparable technology positioning in advanced wound dressings and similar Nordic/European commercial footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amferia

Antimicrobial Wound Care Medical Devicesamferia.com

Amferia is a Swedish medtech company that develops antimicrobial peptide-hydrogel wound dressings that physically kill antibiotic-resistant bacteria, serving veterinary clinics across eight European countries via distribution partners and entering the US human healthcare market following FDA De Novo approval in February 2026.

What Amferia does

Amferia is a Swedish medtech company founded in 2018 that develops and commercializes antimicrobial hydrogel wound dressings based on a proprietary amphiphilic antimicrobial peptide (AMP) hydrogel platform. The core technology permanently conjugates antimicrobial peptides to a hydrogel matrix, protecting them from enzymatic degradation while allowing the peptides to physically puncture bacterial cell membranes, killing 99.99% of bacteria including antibiotic-resistant strains such as MRSA, MDR E. coli, and Pseudomonas aeruginosa. The platform is protected by three patent families granted in Europe, the United States, and China, and the human-care wound dressing received FDA De Novo Classification in February 2026, establishing a new regulatory category for antibacterial peptide-based wound dressings.

The company's commercial operations are concentrated in veterinary/animal health wound care, where its products are sold through a network of distribution partners across eight European countries under the Snögg BactiDefend brand (via Orkla Wound Care for Nordic, Germany, Spain, and Portugal), Biokema (Switzerland), Grovet (Benelux), Magnum Veterinaaria (Baltic States), and Triolab (Sweden). The company generates revenue through B2B hardware sales to veterinary clinics and is now commercializing human-care wound dressings in the United States following FDA approval, with CE marking pending for European human-health launch. Pipeline products include pre-surgery antibacterial patches, antimicrobial sprays developed in collaboration with Medspray, and antibacterial coatings for medical devices such as catheters and implants, alongside potential licensing opportunities for the underlying platform technology.

Amferia operates from a small team of approximately seven people based at the AZ BioVentureHub in Mölndal, Sweden, with a US sales office (Amferia US LLC) in Bonita, California. The company has raised approximately €7M+ in cumulative venture funding from Chalmers Ventures, Almi Invest, and angel investors, including a €3.5M round in December 2025 led by existing shareholders and new investors prominent in global wound care. Strategic leadership includes co-founder Anand Rajasekharan as CEO, co-founder Saba Atefyekta as Sales & Marketing Director (recipient of King Carl XVI Gustaf's New Entrepreneur of the Year Award), and R&D Director Martin Andersson, with recent board additions of former Mölnlycke executive Randy Schwartz and ex-Pfizer/Orexo CEO Nikolaj Sørensen to guide US market entry and global expansion.

Amferia firmographics

Firmographics
Name
Amferia
Legal name
Amferia AB
Website
https://amferia.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Amferia is a Swedish medtech company that develops antimicrobial peptide-hydrogel wound dressings that physically kill antibiotic-resistant bacteria, serving veterinary clinics across eight European countries via distribution partners and entering the US human healthcare market following FDA De Novo approval in February 2026.
Ownership category
akta.pro rank

Amferia industry classification

Industry
Product category
Antimicrobial Wound Care Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Antimicrobial wound dressings
  • Medical device coatings
  • Veterinary wound care
  • Peptide hydrogel technology
  • Antibiotic resistance solutions

Where Amferia is headquartered

Location

Headquarters

HQ city
Mölndal
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Amferia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Animal Health Products: Sale of antimicrobial hydrogel wound dressings for veterinary applications through distribution partners. Products sold under brand names like Snögg BactiDefend through Orkla Wound Care. Revenue generated from product sales to veterinary clinics across Europe.
  2. Human Health Products: Planned revenue from antibacterial wound dressings and other human healthcare applications pending regulatory approvals (FDA, CE marking). Products will be sold through partnerships with established wound care companies or direct commercialization.
  3. Licensing and Partnership Agreements: Technology licensing opportunities for the antimicrobial peptide-hydrogel platform in various medical device applications including coatings, sprays, and implant sterilization.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B wholesale pricing through distribution partners

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Amferia product offering

Product offering

Core offering

Amferia develops and manufactures antimicrobial hydrogel medical products based on a proprietary amphiphilic platform that permanently binds antimicrobial peptides, enabling physical bacterial killing without releasing active substances. Core offerings include veterinary and human wound dressings (AMP Wound Dressing / Snögg BactiDefend), with pipeline products spanning pre-surgery patches, aerosol sprays for deep wounds, and antimicrobial coatings for medical devices such as catheters and implants.

Product overview

Amferia offers an antimicrobial peptide hydrogel platform technology that enables peptides to be used safely in medical devices. The core product is the AMP Wound Dressing for animal health (branded as Snögg BactiDefend Dressing in partnership with Orkla) and the human care Antimicrobial Hydrogel Wound Dressing (which received FDA De Novo Classification in February 2026 as the world's first antibacterial peptide-based wound dressing). Pipeline products include Antibacterial Patches for pre-surgery applications, Antimicrobial Sprays for wound care (developed with Medspray), and Antibacterial Coatings for medical devices such as catheters and implants. The platform technology consists of amphiphilic antimicrobial hydrogels with permanently bonded peptides that physically puncture bacterial membranes, killing 99.99% of bacteria including resistant strains without releasing substances into the body.

Differentiator

Problem solved

Functional benefit

Products and services

  • AMP Wound Dressing (Animal Health) Antimicrobial hydrogel wound dressing for veterinary use that kills up to 99.99% of bacteria upon contact, including antibiotic-resistant strains. The dressing consists of amphiphilic antibacterial polymers mimicking the immune system, bound in place so nothing is released into the wound. For professional veterinary in-clinic use in surgical care units or in-patient care.
  • Snögg BactiDefend Dressing Veterinary wound care product using Amferia's proprietary antimicrobial hydrogel technology, sold under Orkla's Snögg Animal Care brand via exclusive distribution agreement. Designed for professional veterinary use across multiple European countries (Nordic region, Germany, Spain, Portugal).
  • Antimicrobial Hydrogel Wound Dressing (Human Care) Antibacterial wound dressing featuring patented hydrogel permanently bonded with peptides that physically puncture bacterial cell membranes, killing 99.99% of bacteria including antibiotic-resistant strains without releasing active substances into the body or wound. For human patients in hospitals, wound care clinics, and healthcare institutions.
  • Antibacterial Patches (Pre-Surgery) Patch formulation of Amferia hydrogel that clears skin of bacteria before surgical procedures. Demonstrated to kill up to 99.99% of bacteria on skin surface within three hours of application in a clinical study with 40 healthy volunteers.
  • Antimicrobial Spray Aerosol spray formulation of the antimicrobial hydrogel for application directly to wounds or skin. Enables eradication of bacteria from deep and uneven wounds with high surface area coverage. Developed in partnership with Medspray BV via Eurostars Grant (SURPAS project).
  • Antibacterial Coatings (Medical Devices)

Quantifiable outcome

  • 99.99% bacterial kill rate including antibiotic-resistant strains (MRSA, MDR E. Coli, Pseudomonas aeruginosa)
  • +5 more outcomes

Companies that use Amferia

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Amferia technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Amferia partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, flagship and minor.

  • Grovet BVcoreChannel Partner/ Reseller/ Distributor · 5 February 2026Distribution partnership to expand AMP Wound Dressing into Benelux markets (Netherlands, Belgium, Luxembourg). Grovet is a major player in animal health market across Benelux. Products expected to be available by spring 2026.
  • Magnum VeterinaariacoreChannel Partner/ Reseller/ Distributor · 20 January 2026Distribution partnership to expand into Baltic States (Latvia, Lithuania, Estonia). Partnership aims to bring groundbreaking wound care technology to animal patients in the Baltics, helping reduce reliance on antibiotics in veterinary practice.
  • Biokema SAcoreChannel Partner/ Reseller/ Distributor · 26 August 2024Distribution partnership for commercialization of Amferia's wound care technology for animal health in Switzerland. Swiss company founded in 1959 specializing in veterinary pharmaceuticals and products. Products to be marketed starting early 2025.
  • Medspray BVcoreStrategic or Co-development Partner · 26 March 2024Eurostars grant-funded collaboration (SURPAS project) to develop antimicrobial spray for surgical wound care. Medspray provides microdroplet spray technology expertise while Amferia contributes peptide-hydrogel material. Joint project aims to deliver peptide-hydrogel as microdroplet spray with optimal coverage for wound care applications.
  • Orkla Wound Care ABflagshipChannel Partner/ Reseller/ Distributor · 4 December 2023Exclusive animal health private label license and purchase agreement covering Nordic region, Germany, Spain, and Portugal for 3 years with possibility for extension. Products marketed under Orkla's Snögg Animal Care brand. This is Amferia's largest distribution partnership, with Orkla being a publicly listed company on the Norwegian Stock Exchange.
  • TriolabminorChannel Partner/ Reseller/ Distributor · 6 May 2021Distribution partnership to reach Swedish veterinary market. Products marketed to selective veterinary clinics across Sweden with further expansion planned for 2022.
  • Chalmers University of TechnologycoreStrategic or Co-development PartnerResearch collaboration partner where Amferia's technology was originally developed. Ongoing collaboration on new product development, pre-clinical studies, and clinical research. Co-developed mesoporous elastomer technology and spray formulations.
  • AZ BioVentureHubminorOthersLife science innovation hub located in Mölndal, Sweden (formerly AstraZeneca's facility) where Amferia established R&D operations in October 2019. Provides supportive environment with state-of-the-art infrastructure for medtech and life science companies.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Amferia competitors and assessment

Company assessment

Direct peers

  • ConvaTec: Global advanced wound care and ostomy player (Aquacel, Foam dressings). Competes in the same antimicrobial/advanced dressing category and is a logical partner for Amferia's peptide-hydrogel licensing.
  • Smith+Nephew: Major medical device company with significant advanced wound care franchise (Allevyn, PICO). Overlapping customer base (hospitals, wound clinics) and a likely competitor or partner once peptide-based dressings reach commercial scale.
  • Bactiguard: Swedish medtech specializing in antimicrobial coatings for medical devices (catheters, implants) — directly comparable technology adjacency. Amferia board chair Agneta Edberg was previously COO of Bactiguard, underscoring the strategic proximity.
  • Mölnlycke Health Care: One of the world's largest advanced wound care companies (Mepilex, Mepitel, etc.). Direct competitor in advanced wound dressings and Amferia's most likely strategic acquirer or licensing partner; several Amferia board members (Randy Schwartz, Therese Rydell) joined from Mölnlycke.
  • Organogenesis: US advanced wound care company (Apligraf, Dermagraft, PuraPly). Competes in the same wound care category with biologics and skin substitutes; comparable reimbursement-driven US go-to-market motion.
  • Coloplast: Danish medtech with a sizeable wound and skin care business (Biatain, Comfeel). Comparable technology positioning in advanced wound dressings and similar Nordic/European commercial footprint.

Emerging players

  • MiMedx: US-based advanced wound care and surgical recovery company (EpiFix, AmnioFix). Smaller, growth-stage competitor serving similar hospital and outpatient wound care customers.
  • Covalon Technologies: Canadian antimicrobial coating and wound dressing company (e.g., IVClear, ColActive). Smaller and earlier-stage than the majors but addresses the same antimicrobial catheter/coating overlap as Amferia's coating pipeline.

Broad incumbents

  • Integra LifeSciences: Diversified surgical and wound care company (Integra dermal regeneration, wound matrices). Overlaps with Amferia in hospital wound care channels though through different technology.
  • 3M Health Care: Diversified healthcare giant with established advanced wound care dressings (Tegaderm). Comparable end market and channel access but competing as part of a much broader medical portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Amferia social profiles

Digital presence

Amferia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amferia leadership team

Management profile

Number of profiles

Profiles18 records

Amferia subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Amferia funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amferia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amferia

What does Amferia do?

Amferia develops and manufactures antimicrobial hydrogel medical products based on a proprietary amphiphilic platform that permanently binds antimicrobial peptides, enabling physical bacterial killing without releasing active substances. Core offerings include veterinary and human wound dressings (AMP Wound Dressing / Snögg BactiDefend), with pipeline products spanning pre-surgery patches, aerosol sprays for deep wounds, and antimicrobial coatings for medical devices such as catheters and implants.

Is Amferia a public or private company?

Amferia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Amferia founded?

Amferia was founded in 2018. It employs 11 to 50 people.

Where is Amferia based?

Amferia is headquartered in Mölndal, Sweden, in the Europe region.

How does Amferia make money?

Three revenue lines are on record. Animal Health Products are the primary driver. The others are human Health Products and licensing and Partnership Agreements.

Who are Amferia's main competitors?

Direct peers on record are ConvaTec, Smith+Nephew, Bactiguard, Mölnlycke Health Care, Organogenesis and Coloplast. Emerging players are MiMedx and Covalon Technologies. Broad incumbents are Integra LifeSciences and 3M Health Care.

Does Amferia have an API?

No public API is recorded for Amferia.

What industry is Amferia in?

Amferia's product category is Antimicrobial Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comAmferia Strengthens Advanced Wound Care Platform with ISO 13485 Quality CertificationAmferia, a Swedish medtech company, earned ISO 13485 quality certification for its peptide-based antibacterial wound care products. The certification follows its FDA De Novo clearance and confirms a documented quality management system covering the full product lifecycle. The company plans to use the certification to scale operations and bring innovative devices to market.news.cision.comAmferia Reaches Milestone of 33 Granted Patents Across 20 Jurisdictions, Positioning the Company for Growth in the Antimicrobial Wound Care MarketAmferia announced 33 granted patents across 20 jurisdictions, with a portfolio of 50 applications spanning four technology families. The milestone follows FDA De Novo Classification approval and positions the company for commercial development. New patents are in active development for the antimicrobial wound care platform.news.cision.comAmferia Annual General Meeting (AGM) Appoints Global Healthcare Leaders Randy Schwartz and Nikolaj Sørensen to Board of DirectorsAmferia's AGM appointed Randy Schwartz and Nikolaj Sørensen to its board, following the FDA's De Novo classification for its antibacterial wound dressing. The company is preparing to accelerate its US commercial entry, with Schwartz and Sørensen bringing expertise in wound care and international strategy. Amferia also readies EU clinical data for human treatments.news.cision.comFollowing the U.S. FDA De Novo Classification, Amferia Seeks Potential Partners to Market the World’s First Antibacterial Peptide-Based Wound DressingSwedish medtech firm Amferia AB has been granted FDA De Novo Classification for its antibacterial wound dressing, making it the first-ever wound care product using antibacterial peptides as the mechanism for fighting infection and establishing a new regulatory category for wound dressings in the United States. The company, which raised €3.5 million in December 2025, is now seeking strategic partners to bring the product to the U.S. market and is attending the EWMA Congress in Germany to discuss expansion. Amferia is also preparing clinical data to pursue approval for human care within the European Union.news.cision.comAmferia Signs Major Animal Health Distribution Contract with Interchem (Ireland) Ltd, Expanding into IrelandAmferia signed a distribution partnership with Interchem (Ireland) Ltd to bring its AMP Wound Dressing to Irish veterinary professionals. The launch is scheduled for Spring 2026, expanding Amferia's European footprint beyond Scandinavia, Germany, Spain, and Switzerland.ChalmersChalmers-based Amferia receives FDA approval for a new type of wound care productAmferia, a Chalmers-based biotech company in Sweden, received FDA approval for its innovative wound care product—a hydrogel platform that encases antibacterial peptides to effectively kill antibiotic-resistant bacteria. The technology solves a major challenge by protecting fragile peptides from natural enzymes in the body, enabling them to target and destroy bacteria without harming surrounding tissue. The approval establishes a new regulatory category for wound dressings and positions Amferia as a strategic partner for wound care companies, with the company planning to expand applications of its peptide-based technology beyond wound care into other markets.news.cision.comFDA Grants De Novo Classification Request to Market the World’s First Antibacterial Peptide-Based Wound DressingThe FDA has granted De Novo Classification approval to Swedish medtech firm Amferia to market the world's first antibacterial peptide-based wound dressing in the United States, creating a new regulatory category for antimicrobial wound dressings. The dressing uses a hydrogel permanently bonded with peptides that physically puncture bacterial cell membranes, killing 99.99% of bacteria including antibiotic-resistant strains without releasing active substances into the body or wound. With FDA approval secured, Amferia is positioned as a strategic partner for wound care companies seeking next-generation antimicrobial solutions and plans to expand the technology beyond wound care.news.cision.comAmferia signs major contract in Animal Health with Grovet BV and Expands into the Benelux marketsAmferia AB, a Swedish medtech company developing antimicrobial wound-care solutions, announced a distribution partnership with Grovet BV to expand its AMP Wound Dressing into the Benelux markets (Netherlands, Belgium, Luxembourg), with products expected to be available by spring 2026. The partnership leverages Amferia's breakthrough hydrogel technology that encases antimicrobial peptides in a protective gel, enabling them to kill antibiotic-resistant bacteria by puncturing bacterial cell membranes without enzyme degradation. Grovet, as a major player in the animal health market across Benelux, will help advance Amferia's footprint in Europe where products are already available in Scandinavia, Germany, Spain, and Switzerland.news.cision.comMedtech Firm Amferia Secures €3.5M Investment to Accelerate Breakthrough Antimicrobial Technology in Human and Animal HealthAmferia, a Swedish medtech company, announced the closing of a €3.5 million investment round to advance its antimicrobial wound-care solutions for human and animal health. The funding will support clinical development, regulatory approvals, and expansion of its veterinary products.AmferiaAmferia – NewsThe FDA granted Amferia De Novo Classification to market the world's first antibacterial peptide-based wound dressing in the United States, establishing a new regulatory category for wound dressings. The Swedish medtech firm's patented hydrogel technology permanently bonded with peptides physically punctures bacterial cell membranes, killing 99.99% of bacteria including antibiotic-resistant strains without releasing active substances into the wound or body. Amferia CEO Anand Rajasekharan stated the approval validates years of scientific and regulatory work and opens doors to safer antimicrobial strategies at a time when bacterial infections are projected to become a leading cause of death globally.